TY - JOUR
T1 - Cooperative effect of complementary antisense oligonucleotides and CRISPR effectors for universal DNA-based pathogen assay using nano-enabled colorimetry
AU - Dighe, Ketan
AU - Moitra, Parikshit
AU - Saha, Pranay
AU - Gunaseelan, Nivetha
AU - Pan, Dipanjan
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/11
Y1 - 2024/11
N2 - Infectious diseases continue to pose significant challenges to global health, necessitating the development of diagnostic methodologies that are not only rapid and precise but also universally accessible. Herein, we developed a colorimetric CRISPR-Cas12a assay that utilizes CRISPR gene-editing technology, gold nanoparticles (AuNPs), and DNA hybridization principles to target a range of antibiotic-resistant and emerging pathogens, including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Candida auris (CA), and Human Papillomavirus (HPV). The assay utilizes specially engineered CRISPR-RNA (crRNA) and single-stranded oligonucleotides (ssDNAs) that correspond to a complementary single-stranded DNA sequence, termed the ’linker probe,’ which targets conserved genetic regions to enhance specificity and sensitivity. This design facilitates a simple visual readout through significant changes in the optical properties of AuNPs when the Cas12a enzyme, activated by target DNA, cleaves the linker probe. The assay, which does not require DNA amplification, demonstrated the ability to detect these pathogens with a detection limit of 7–8 copies/µL and achieved a clinical sensitivity of 100 % in detecting Chlamydia trachomatis and Neisseria gonorrhoeae from 60 de-identified clinical samples. Additionally, it directly detects DNA from these pathogens without the need for DNA extraction, employing a multiplexed lateral flow-based platform suitable for rapid clinical monitoring. This novel diagnostic approach offers significant improvements in the detection and management of infectious diseases, particularly in resource-limited settings, due to its simplicity, cost-effectiveness, and high specificity and sensitivity.
AB - Infectious diseases continue to pose significant challenges to global health, necessitating the development of diagnostic methodologies that are not only rapid and precise but also universally accessible. Herein, we developed a colorimetric CRISPR-Cas12a assay that utilizes CRISPR gene-editing technology, gold nanoparticles (AuNPs), and DNA hybridization principles to target a range of antibiotic-resistant and emerging pathogens, including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Candida auris (CA), and Human Papillomavirus (HPV). The assay utilizes specially engineered CRISPR-RNA (crRNA) and single-stranded oligonucleotides (ssDNAs) that correspond to a complementary single-stranded DNA sequence, termed the ’linker probe,’ which targets conserved genetic regions to enhance specificity and sensitivity. This design facilitates a simple visual readout through significant changes in the optical properties of AuNPs when the Cas12a enzyme, activated by target DNA, cleaves the linker probe. The assay, which does not require DNA amplification, demonstrated the ability to detect these pathogens with a detection limit of 7–8 copies/µL and achieved a clinical sensitivity of 100 % in detecting Chlamydia trachomatis and Neisseria gonorrhoeae from 60 de-identified clinical samples. Additionally, it directly detects DNA from these pathogens without the need for DNA extraction, employing a multiplexed lateral flow-based platform suitable for rapid clinical monitoring. This novel diagnostic approach offers significant improvements in the detection and management of infectious diseases, particularly in resource-limited settings, due to its simplicity, cost-effectiveness, and high specificity and sensitivity.
UR - http://www.scopus.com/inward/record.url?scp=85206269211&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85206269211&partnerID=8YFLogxK
U2 - 10.1016/j.mattod.2024.09.017
DO - 10.1016/j.mattod.2024.09.017
M3 - Article
AN - SCOPUS:85206269211
SN - 1369-7021
VL - 80
SP - 374
EP - 394
JO - Materials Today
JF - Materials Today
ER -